FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2403005587> ?p ?o ?g. }

• W2403005587 abstract "Postremission therapy for acute myeloid leukemia (AML) is critical for elimination of minimal residual disease (MRD). In patients not eligible for allogeneic stem cell transplantation, alternative treatment options are needed. Therapeutic vaccination with autologous dendritic cells (DCs) loaded with leukemia-associated antigens (LAAs) is a promising treatment strategy to induce anti-leukemic immune responses and to eradicate chemorefractory cells. We have developed a GMP-compliant 3-day protocol including a TLR7/8 agonist to differentiate monocytes of intensively pretreated AML patients into next-generation DCs. A phase I proof-of-concept study (n=6) was completed using next-generation DCs as postremission therapy of AML patients with a non-favorable genetic risk profile in CR after intensive induction therapy ( NCT01734304 ), and we have already started enrollment into a phase II trial building on these results. DCs are loaded with ivt -RNA encoding the LAAs WT1 and PRAME as well as CMVpp65 as adjuvant and surrogate antigen. Patients are vaccinated intradermally with 5x10 6 DCs of each antigen species up to 10 times within 26 weeks. The primary endpoint of the phase I trial is feasibility and safety of the vaccination. Secondary endpoints are immunological responses and disease control. In total, 10 patients have been enrolled into the phase I/II trial. With two screening failures, DCs of sufficient number and quality were generated from leukapheresis in 7/8 cases. DC analysis demonstrated a positive costimulatory profile, secretion of IL-12p70, migration towards a chemokine gradient, antigen processing and presentation and activation of specific T cells in vitro . 5 patients have completed the vaccination schedule; the 6th patient has received 4/10 vaccinations. We observed delayed-type hypersensitivity (DTH) responses at the vaccination site in 5/5 patients, accompanied by slight erythema and indurations at the injection site, but no grade III/IV toxicities. Multimer analysis revealed the induction of antigen-specific T cell responses in 3/3 patients tested. We detected an increase of WT1-specific T cells in one patient and strong inductions of CMVpp65-specific T cells in two CMV-seronegative patients. TCR repertoire analysis by next-generation sequencing revealed an enrichment of particular clonotypes at DTH sites. In an individual treatment attempt, we treated one patient with impending relapse with a combination of DC vaccination and 5-azacytidine, resulting in MRD conversion. From the results of our phase I trial, we conclude that vaccination with next-generation DCs in AML is feasible and safe and induces leukemia-specific immune responses in vivo . The protocol is continued to be studied in an ongoing phase II trial. Citation Format: Felix S. Lichtenegger, Frauke M. Schnorfeil, Thomas Kohnke, Torben Altmann, Veit Bucklein, Andreas Moosmann, Monika Bruggemann, Beate Wagner, Wolfgang Hiddemann, Iris Bigalke, Gunnar Kvalheim, Marion Subklewe. Next-generation dendritic cell vaccination in postremission therapy of AML: Results of a clinical phase I trial. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr B146." @default.
• W2403005587 created "2016-06-24" @default.
• W2403005587 creator A5003069482 @default.
• W2403005587 creator A5009874210 @default.
• W2403005587 creator A5033935778 @default.
• W2403005587 creator A5054447908 @default.
• W2403005587 creator A5063176873 @default.
• W2403005587 creator A5066818291 @default.
• W2403005587 creator A5067305238 @default.
• W2403005587 creator A5069712978 @default.
• W2403005587 creator A5075073484 @default.
• W2403005587 creator A5086730170 @default.
• W2403005587 creator A5089965167 @default.
• W2403005587 creator A5068979347 @default.
• W2403005587 date "2016-01-01" @default.
• W2403005587 modified "2023-09-27" @default.
• W2403005587 title "Abstract B146: Next-generation dendritic cell vaccination in postremission therapy of AML: Results of a clinical phase I trial" @default.
• W2403005587 doi "https://doi.org/10.1158/2326-6074.cricimteatiaacr15-b146" @default.
• W2403005587 hasPublicationYear "2016" @default.
• W2403005587 type Work @default.
• W2403005587 sameAs 2403005587 @default.
• W2403005587 citedByCount "0" @default.
• W2403005587 crossrefType "proceedings-article" @default.
• W2403005587 hasAuthorship W2403005587A5003069482 @default.
• W2403005587 hasAuthorship W2403005587A5009874210 @default.
• W2403005587 hasAuthorship W2403005587A5033935778 @default.
• W2403005587 hasAuthorship W2403005587A5054447908 @default.
• W2403005587 hasAuthorship W2403005587A5063176873 @default.
• W2403005587 hasAuthorship W2403005587A5066818291 @default.
• W2403005587 hasAuthorship W2403005587A5067305238 @default.
• W2403005587 hasAuthorship W2403005587A5068979347 @default.
• W2403005587 hasAuthorship W2403005587A5069712978 @default.
• W2403005587 hasAuthorship W2403005587A5075073484 @default.
• W2403005587 hasAuthorship W2403005587A5086730170 @default.
• W2403005587 hasAuthorship W2403005587A5089965167 @default.
• W2403005587 hasConcept C10205521 @default.
• W2403005587 hasConcept C126322002 @default.
• W2403005587 hasConcept C143998085 @default.
• W2403005587 hasConcept C147483822 @default.
• W2403005587 hasConcept C203014093 @default.
• W2403005587 hasConcept C22070199 @default.
• W2403005587 hasConcept C2777371436 @default.
• W2403005587 hasConcept C2777701055 @default.
• W2403005587 hasConcept C2777863537 @default.
• W2403005587 hasConcept C2778170410 @default.
• W2403005587 hasConcept C2778461978 @default.
• W2403005587 hasConcept C2778729363 @default.
• W2403005587 hasConcept C2779282312 @default.
• W2403005587 hasConcept C2779823535 @default.
• W2403005587 hasConcept C28328180 @default.
• W2403005587 hasConcept C2911091166 @default.
• W2403005587 hasConcept C54355233 @default.
• W2403005587 hasConcept C71924100 @default.
• W2403005587 hasConcept C86803240 @default.
• W2403005587 hasConcept C8891405 @default.
• W2403005587 hasConceptScore W2403005587C10205521 @default.
• W2403005587 hasConceptScore W2403005587C126322002 @default.
• W2403005587 hasConceptScore W2403005587C143998085 @default.
• W2403005587 hasConceptScore W2403005587C147483822 @default.
• W2403005587 hasConceptScore W2403005587C203014093 @default.
• W2403005587 hasConceptScore W2403005587C22070199 @default.
• W2403005587 hasConceptScore W2403005587C2777371436 @default.
• W2403005587 hasConceptScore W2403005587C2777701055 @default.
• W2403005587 hasConceptScore W2403005587C2777863537 @default.
• W2403005587 hasConceptScore W2403005587C2778170410 @default.
• W2403005587 hasConceptScore W2403005587C2778461978 @default.
• W2403005587 hasConceptScore W2403005587C2778729363 @default.
• W2403005587 hasConceptScore W2403005587C2779282312 @default.
• W2403005587 hasConceptScore W2403005587C2779823535 @default.
• W2403005587 hasConceptScore W2403005587C28328180 @default.
• W2403005587 hasConceptScore W2403005587C2911091166 @default.
• W2403005587 hasConceptScore W2403005587C54355233 @default.
• W2403005587 hasConceptScore W2403005587C71924100 @default.
• W2403005587 hasConceptScore W2403005587C86803240 @default.
• W2403005587 hasConceptScore W2403005587C8891405 @default.
• W2403005587 hasLocation W24030055871 @default.
• W2403005587 hasOpenAccess W2403005587 @default.
• W2403005587 hasPrimaryLocation W24030055871 @default.
• W2403005587 hasRelatedWork W1001858044 @default.
• W2403005587 hasRelatedWork W1978948371 @default.
• W2403005587 hasRelatedWork W2045069992 @default.
• W2403005587 hasRelatedWork W2053626826 @default.
• W2403005587 hasRelatedWork W2065398026 @default.
• W2403005587 hasRelatedWork W2077608431 @default.
• W2403005587 hasRelatedWork W2092278351 @default.
• W2403005587 hasRelatedWork W2220843277 @default.
• W2403005587 hasRelatedWork W2340931641 @default.
• W2403005587 hasRelatedWork W2546490469 @default.
• W2403005587 hasRelatedWork W2547771657 @default.
• W2403005587 hasRelatedWork W2564288279 @default.
• W2403005587 hasRelatedWork W2586622525 @default.
• W2403005587 hasRelatedWork W2606303171 @default.
• W2403005587 hasRelatedWork W2980045473 @default.
• W2403005587 hasRelatedWork W2980132384 @default.
• W2403005587 hasRelatedWork W2983686108 @default.
• W2403005587 hasRelatedWork W3010583755 @default.
• W2403005587 hasRelatedWork W3093184135 @default.
• W2403005587 hasRelatedWork W3101962529 @default.
• W2403005587 isParatext "false" @default.
• W2403005587 isRetracted "false" @default.

• next